©Sararwut Jaimassiri/shutterstock.com


What genomic changes do EGFR TARGET and EGRF MONITOR tests detect?

The EGFR TARGET is a test that detects 42 different changes in exons 18, 19, 20 and 21 of the epidermal growth factor receptor (EGFR) from a blood sample. Some of these mutations lead to a permanent activation of the receptor, which favors tumor growth. Therapy with EGFR tyrosine kinase inhibitors (TKI) (gefitinib, erlotinib and afatanib) blocks the action of the EGF receptor and thus inhibits tumor growth. The detection of an EGF receptor-activating mutation in the blood can reveal whether a tumor will respond to such therapy, which is the case in approximately 10% in non-small cell lung carcinoma among Europeans.

In some cases, such a mutation can be detected in the plasma, although it could not be detected in a biopsy.

However, therapy with traditional TheraSure-EGFR-TKIs often leads to the occurrence of so-called resistance mutations, which render these drugs ineffective. The most common of these (about 50%) is EGFR-p.T790M and is screened with EGFR MONITOR. If this mutation is discovered at an early stage by means of a LIQUID BIOPSY, your doctor can react with a conversion of the therapy.

For whom is the EGFR TARGET test suitable?

Patients with non-small cell lung carcinoma or other tumors who are to receive an EGFR-TKI.

For whom is the EGFR MONITOR test suitable?

Patients with non-small-cell lung carcinoma or other tumors already receiving EGFR-TKI therapy.

What do the tests do?

The EGFR TARGET test detects the most common activating and resistance mutations in the EGFR gene. The detection of these mutations in your blood sample provides your doctor with vital information for initiating the optimal therapy for you. The sensitivity of the test depends on the amounts of circulating tumor DNA contained in the sample, which is individually different and depends on several factors. A negative result therefore does not exclude the presence of mutations below the detection limit.

The EGFR MONITOR test detects the most common resistance mutation T790M with high sensitivity; it can give an early indication of an emerging resistance of the tumor against the currently used drug and is therefore particularly suitable for monitoring the therapy.

How does the test work?

The blood sampling is taken in a special tube, which we send after your order to a doctor of your choice. After we have received the blood sample, the result will be available within about two weeks.

Our laboratory is specialized in the above-described analysis. Our state-of-the-art procedures are subject to constant quality control so that we can guarantee you the best possible quality of testing.

©Tomislav Forgo/shutterstock.com

How can we help you?

Do you have any questions about our laboratory services, our service and consulting offerings or are you looking for further information? We would like to help you.

send us a request
Phone: 0800 5478432
Fax: 0800 5246779